Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Down 50.2% in October

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) saw a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 13,800 shares, a drop of 50.2% from the October 15th total of 27,700 shares. Based on an average daily trading volume, of 158,500 shares, the short-interest ratio is presently 0.1 days.

Biodexa Pharmaceuticals Price Performance

NASDAQ:BDRX traded down $1.24 during mid-day trading on Friday, reaching $3.62. The company’s stock had a trading volume of 64,761 shares, compared to its average volume of 127,394. Biodexa Pharmaceuticals has a 12-month low of $3.51 and a 12-month high of $220.25.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.